Center-Authored Papers

Filters: Author is Kurzrock, Razelle  [Clear All Filters]
Journal Article
Munster PN, Aggarwal R, Hong D, Schellens JHM, van der Noll R, Specht J, Witteveen PO, Werner T, Dees CE, Bergsland EK et al..  2015.  First-in-human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-kinase inhibitor, in Patients with Advanced Solid Tumor Malignancies.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, Simpson D, Liu AY, Menke D, Chandrakasan S et al..  2017.  International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.. Blood. Abstract
Kurzrock R, Colevas DA, Olszanski A, Akerley W, Arteaga CL, Carson WE, Clark JW, Dipersio JF, Ettinger DS, Morgan RJ et al..  2015.  NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys.. Journal of the National Comprehensive Cancer Network : JNCCN. 13(11):1337-46. Abstract
Venook AP, Arcila ME, Benson AB, Berry DA, Camidge DR, Carlson RW, Choueiri TK, Guild V, Kalemkerian GP, Kurzrock R et al..  2014.  NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.. Journal of the National Comprehensive Cancer Network : JNCCN. 12(11):1629-49. Abstract
van Rhee F, Casper C, Voorhees PM, Fayad LE, van de Velde H, Vermeulen J, Qin X, Qi M, Tromp B, Kurzrock R.  2015.  A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease.. Oncotarget. 6(30):30408-30419. Abstract
Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, Borghaei H, Jagannath S, Sokol L, Usmani S et al..  2013.  A Phase I, Open-Label Study of Siltuximab, an Anti-IL-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
Tsimberidou AM, Estey E, Wen S, Pierce S, Kantarjian H, Albitar M, Kurzrock R.  2008.  The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes.. Cancer. 113(7):1605-13. Abstract
van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, Sokol L, Crawford J, Cornfeld M, Qi M et al..  2010.  Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(23):3701-8. Abstract